Owen B Spiller

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6758386/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The complement system: History, pathways, cascade and inhibitors. European Journal of Microbiology and Immunology, 2012, 2, 103-111.	1.5	234
2	Balancing mcr-1 expression and bacterial survival is a delicate equilibrium between essential cellular defence mechanisms. Nature Communications, 2017, 8, 2054.	5.8	157
3	Complement Regulation by Kaposi's Sarcoma-Associated Herpesvirus ORF4 Protein. Journal of Virology, 2003, 77, 592-599.	1.5	91
4	The relevance of complement to virus biology. Virology, 2004, 319, 176-184.	1.1	90
5	Association Between Pulmonary Ureaplasma Colonization and Bronchopulmonary Dysplasia in Preterm Infants. Pediatric Infectious Disease Journal, 2014, 33, 697-702.	1.1	84
6	Off to a slow start: Under-development of the complement system in term newborns is more substantial following premature birth. Immunobiology, 2012, 217, 176-186.	0.8	83
7	Concurrent Titration and Determination of Antibiotic Resistance in <i>Ureaplasma</i> Species with Identification of Novel Point Mutations in Genes Associated with Resistance. Antimicrobial Agents and Chemotherapy, 2009, 53, 2020-2027.	1.4	73
8	Altered expression of host-encoded complement regulators on human cytomegalovirus-infected cells. European Journal of Immunology, 1996, 26, 1532-1538.	1.6	71
9	Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities. Immunology, 2000, 100, 462-470.	2.0	71
10	Functional Activity of the Complement Regulator Encoded by Kaposi's Sarcoma-associated Herpesvirus. Journal of Biological Chemistry, 2003, 278, 9283-9289.	1.6	71
11	Prevention of Cardiac Dysfunction in Acute Coxsackievirus B3 Cardiomyopathy by Inducible Expression of a Soluble Coxsackievirus-Adenovirus Receptor. Circulation, 2009, 120, 2358-2366.	1.6	67
12	Cytokine-mediated up-regulation of CD55 and CD59 protects human hepatoma cells from complement attack. Clinical and Experimental Immunology, 2000, 121, 234-241.	1.1	64
13	Antibiotic resistance among <i>Ureaplasma</i> spp. isolates: cause for concern?. Journal of Antimicrobial Chemotherapy, 2017, 72, 330-337.	1.3	63
14	Inhibition of Coxsackie B Virus Infection by Soluble Forms of Its Receptors: Binding Affinities, Altered Particle Formation, and Competition with Cellular Receptors. Journal of Virology, 2005, 79, 12016-12024.	1.5	61
15	Mechanism of Neutrophil Dysfunction: Neutrophil Serine Proteases Cleave and Inactivate the C5a Receptor. Journal of Immunology, 2014, 192, 1787-1795.	0.4	60
16	Mapping CD55 Function. Journal of Biological Chemistry, 2003, 278, 10691-10696.	1.6	59
17	Soluble Recombinant Coxsackievirus and Adenovirus Receptor Abrogates Coxsackievirus B3–Mediated Pancreatitis and Myocarditis in Mice. Journal of Infectious Diseases, 2004, 189, 1431-1439.	1.9	56
18	Role of pulmonary infection in the development of chronic lung disease of prematurity. European Respiratory Journal, 2011, 37, 1424-1430.	3.1	53

#	Article	IF	CITATIONS
19	Cervical epithelial damage promotes Ureaplasma parvum ascending infection, intrauterine inflammation and preterm birth induction in mice. Nature Communications, 2020, 11, 199.	5.8	52
20	Antibiotic Resistance among Clinical Ureaplasma Isolates Recovered from Neonates in England and Wales between 2007 and 2013. Antimicrobial Agents and Chemotherapy, 2016, 60, 52-56.	1.4	51
21	Neutralization of Cytomegalovirus Virions: The Role of Complement. Journal of Infectious Diseases, 1997, 176, 339-347.	1.9	48
22	Relationship of proteinases and proteinase inhibitors with microbial presence in chronic lung disease of prematurity. Thorax, 2010, 65, 246-251.	2.7	47
23	Dissecting the Regions of Virion-Associated Kaposi's Sarcoma-Associated Herpesvirus Complement Control Protein Required for Complement Regulation and Cell Binding. Journal of Virology, 2006, 80, 4068-4078.	1.5	45
24	Comparison of full gyrA, gyrB, parC and parE gene sequences between all Ureaplasma parvum and Ureaplasma urealyticum serovars to separate true fluoroquinolone antibiotic resistance mutations from non-resistance polymorphism. Journal of Antimicrobial Chemotherapy, 2009, 64, 529-538.	1.3	45
25	Virus-Host Coevolution in a Persistently Coxsackievirus B3-Infected Cardiomyocyte Cell Line. Journal of Virology, 2011, 85, 13409-13419.	1.5	45
26	Mycoplasma pneumoniae Epidemiology in England and Wales: A National Perspective. Frontiers in Microbiology, 2016, 7, 157.	1.5	43
27	The Kaposi's sarcoma-associated herpesvirus complement control protein (KCP) binds to heparin and cell surfaces via positively charged amino acids in CCP1–2. Molecular Immunology, 2006, 43, 1665-1675.	1.0	42
28	Maternal Intravenous Treatment with either Azithromycin or Solithromycin Clears Ureaplasma parvum from the Amniotic Fluid in an Ovine Model of Intrauterine Infection. Antimicrobial Agents and Chemotherapy, 2014, 58, 5413-5420.	1.4	41
29	Development of a Multilocus Sequence Typing Scheme for Molecular Typing of Mycoplasma pneumoniae. Journal of Clinical Microbiology, 2015, 53, 3195-3203.	1.8	41
30	Coxsackievirus B3-Associated Myocardial Pathology and Viral Load Reduced by Recombinant Soluble Human Decay-Accelerating Factor in Mice. Laboratory Investigation, 2003, 83, 75-85.	1.7	40
31	Synergic Activation of Toll-Like Receptor (TLR) 2/6 and 9 in Response to Ureaplasma parvum & urealyticum in Human Amniotic Epithelial Cells. PLoS ONE, 2013, 8, e61199.	1.1	39
32	Compensatory mutations modulate the competitiveness and dynamics of plasmid-mediated colistin resistance in <i>Escherichia coli</i> clones. ISME Journal, 2020, 14, 861-865.	4.4	38
33	Echoviruses and Coxsackie B Viruses That Use Human Decayâ€Accelerating Factor (DAF) as a Receptor Do Not Bind the Rodent Analogues of DAF. Journal of Infectious Diseases, 2000, 181, 340-343.	1.9	37
34	Tissue distribution of the rat analogue of decayâ€accelerating factor. Immunology, 1999, 97, 374-384.	2.0	36
35	Membrane complement regulators protect against the development of type II collagen-induced arthritis in rats. Arthritis and Rheumatism, 2001, 44, 2425-2434.	6.7	36
36	The Kaposi's Sarcoma-associated Herpesvirus Complement Control Protein Mimics Human Molecular Mechanisms for Inhibition of the Complement System. Journal of Biological Chemistry, 2004, 279, 45093-45101.	1.6	35

#	Article	IF	CITATIONS
37	Efficient generation of monoclonal antibodies against surface-expressed proteins by hyperexpression in rodent cells. Journal of Immunological Methods, 1999, 224, 51-60.	0.6	32
38	Development of a model for cytomegalovirus infection of oligodendrocytes Journal of General Virology, 1997, 78, 3349-3356.	1.3	32
39	Antibodyâ€Independent Activation of the Classical Complement Pathway by Cytomegalovirusâ€Infected Fibroblasts. Journal of Infectious Diseases, 1998, 178, 1597-1603.	1.9	28
40	Inactivation of IL-6 and soluble IL-6 receptor by neutrophil derived serine proteases in cystic fibrosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2010, 1802, 649-658.	1.8	28
41	Repeated maternal intramuscular or intraamniotic erythromycin incompletely resolves intrauterine Ureaplasma parvum infection in a sheep model of pregnancy. American Journal of Obstetrics and Gynecology, 2014, 211, 134.e1-134.e9.	0.7	27
42	Mycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016. Eurosurveillance, 2020, 25, .	3.9	27
43	Decay-accelerating factor expression in the rat kidney is restricted to the apical surface of podocytes. Kidney International, 2002, 62, 2010-2021.	2.6	26
44	Improved Gene Delivery to Intestinal Mucosa by Adenoviral Vectors Bearing Subgroup B and D Fibers. Journal of Virology, 2006, 80, 2747-2759.	1.5	26
45	Characterization of the Complement Inhibitory Function of Rhesus Rhadinovirus Complement Control Protein (RCP). Journal of Biological Chemistry, 2009, 284, 505-514.	1.6	23
46	Echovirus infection of rhabdomyosarcoma cells is inhibited by antiserum to the complement control protein CD59. Microbiology (United Kingdom), 2000, 81, 1393-1401.	0.7	23
47	The viral aetiology of croup and recurrent croup. Archives of Disease in Childhood, 2009, 94, 359-360.	1.0	22
48	The Paradoxical Effects of Chronic Intra-Amniotic <i>Ureaplasma parvum</i> Exposure on Ovine Fetal Brain Development. Developmental Neuroscience, 2017, 39, 472-486.	1.0	22
49	Complement expression on astrocytes and astrocytoma cell lines: failure of complement regulation at the C3 level correlates with very low CD55 expression. Journal of Neuroimmunology, 1996, 71, 97-106.	1.1	21
50	Probing the Interaction between Feline Immunodeficiency Virus and CD134 by Using the Novel Monoclonal Antibody 7D6 and the CD134 (O×40) Ligand. Journal of Virology, 2007, 81, 9665-9679.	1.5	21
51	Maternal Intravenous Administration of Azithromycin Results in Significant Fetal Uptake in a Sheep Model of Second Trimester Pregnancy. Antimicrobial Agents and Chemotherapy, 2014, 58, 6581-6591.	1.4	21
52	Coxsackie B viruses that use human DAF as a receptor infect pig cells via pig CAR and do not use pig DAF. Journal of General Virology, 2002, 83, 45-52.	1.3	21
53	Random insertion and gene disruption via transposon mutagenesis of Ureaplasma parvum using a mini-transposon plasmid. International Journal of Medical Microbiology, 2014, 304, 1218-1225.	1.5	20
54	Outside-in? Acute fetal systemic inflammation in very preterm chronically catheterized sheep fetuses is not driven by cells in the fetal blood. American Journal of Obstetrics and Gynecology, 2016, 214, 281.e1-281.e10.	0.7	20

#	Article	IF	CITATIONS
55	Kaposi's sarcoma-associated herpes virus complement control protein: KCP – complement inhibition and more. Molecular Immunology, 2007, 44, 11-22.	1.0	18
56	Growth characteristics of human adenoviruses on porcine cell lines. Virology, 2008, 373, 400-410.	1.1	18
57	High-Resolution Melt PCR Analysis for Genotyping of Ureaplasma parvum Isolates Directly from Clinical Samples. Journal of Clinical Microbiology, 2014, 52, 599-606.	1.8	18
58	Human Diffusely Adhering Escherichia coli Expressing Afa/Dr Adhesins That Use Human CD55 (Decay-Accelerating Factor) as a Receptor Does Not Bind the Rodent and Pig Analogues of CD55. Infection and Immunity, 2004, 72, 4859-4863.	1.0	16
59	Molecular Characterization of the Rhesus Rhadinovirus (RRV) ORF4 Gene and the RRV Complement Control Protein It Encodes. Journal of Virology, 2007, 81, 4166-4176.	1.5	16
60	Serum killing of Ureaplasma parvum shows serovar-determined susceptibility for normal individuals and common variable immuno-deficiency patients. Immunobiology, 2012, 217, 187-194.	0.8	16
61	MYCO WELL D-ONE detection of Ureaplasma spp. and Mycoplasma hominis in sexual health patients in Wales. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 2427-2440.	1.3	16
62	Antimicrobial activity of Manuka honey against antibiotic-resistant strains of the cell wall-free bacteria <i>Ureaplasma parvum</i> and <i>Ureaplasma urealyticum</i> . Letters in Applied Microbiology, 2017, 64, 198-202.	1.0	14
63	Chronic Intra-Uterine Ureaplasma parvum Infection Induces Injury of the Enteric Nervous System in Ovine Fetuses. Frontiers in Immunology, 2020, 11, 189.	2.2	13
64	<i>Legionella</i> antibiotic susceptibility testing: is it time for international standardization and evidence-based guidance?. Journal of Antimicrobial Chemotherapy, 2021, 76, 1113-1116.	1.3	13
65	Tetracycline Resistance Mediated by <i>tet</i> (M) Has Variable Integrative Conjugative Element Composition in Mycoplasma hominis Strains Isolated in the United Kingdom from 2005 to 2015. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	13
66	Susceptibility of B lymphocytes to adenovirus type 5 infection is dependent upon both coxsackie–adenovirus receptor and αvβ5 integrin expression. Journal of General Virology, 2005, 86, 1669-1679.	1.3	13
67	Pulmonary vascular changes in extremely preterm sheep after intra-amniotic exposure to Ureaplasma parvum and lipopolysaccharide. PLoS ONE, 2017, 12, e0180114.	1.1	13
68	Comparing Long-Read Assemblers to Explore the Potential of a Sustainable Low-Cost, Low-Infrastructure Approach to Sequence Antimicrobial Resistant Bacteria With Oxford Nanopore Sequencing. Frontiers in Microbiology, 2022, 13, 796465.	1.5	13
69	In vitro activity of solithromycin and its metabolites, CEM-214 and N-acetyl-CEM-101, against 100 clinical Ureaplasma spp. isolates compared with azithromycin. International Journal of Antimicrobial Agents, 2015, 46, 319-324.	1.1	12
70	Intrauterine Candida albicans Infection Causes Systemic Fetal Candidiasis With Progressive Cardiac Dysfunction in a Sheep Model of Early Pregnancy. Reproductive Sciences, 2017, 24, 77-84.	1.1	12
71	Prevalent human coxsackie B-5 virus infects porcine islet cells primarily using the coxsackie-adenovirus receptor. Xenotransplantation, 2004, 11, 536-546.	1.6	10
72	More recent swine vesicular disease virus isolates retain binding to coxsackie–adenovirus receptor, but have lost the ability to bind human decay-accelerating factor (CD55). Journal of General Virology, 2005, 86, 1369-1377.	1.3	10

#	Article	IF	CITATIONS
73	Genomic determination of minimum multi-locus sequence typing schemas to represent the genomic phylogeny of Mycoplasma hominis. BMC Genomics, 2016, 17, 964.	1.2	10
74	Environmental surveillance of ESBL and carbapenemase-producing gram-negative bacteria in a Ghanaian Tertiary Hospital. Antimicrobial Resistance and Infection Control, 2022, 11, 49.	1.5	10
75	Antibodies against Kaposi sarcoma-associated herpes virus (KSHV) complement control protein (KCP) in infected individuals. Vaccine, 2007, 25, 8102-8109.	1.7	9
76	Protection of the Ovine Fetal Gut against Ureaplasma-Induced Chorioamnionitis: A Potential Role for Plant Sterols. Nutrients, 2019, 11, 968.	1.7	9
77	Separation of decay-accelerating and cofactor functional activities of Kaposi's sarcoma-associated herpesvirus complement control protein using monoclonal antibodies. Immunology, 2007, 123, 070903002036001-???.	2.0	7
78	<i>Legionella</i> antimicrobial sensitivity testing: comparison of microbroth dilution with BCYE and LASARUS solid media. Journal of Antimicrobial Chemotherapy, 2021, 76, 1197-1204.	1.3	7
79	Emerging Pathogenic Respiratory Mycoplasma hominis Infections in Lung Transplant Patients: Time to Reassesses it's Role as a Pathogen?. EBioMedicine, 2017, 19, 8-9.	2.7	6
80	Foetal <i>Ureaplasma parvum</i> bacteraemia as a function of gestationâ€dependent complement insufficiency: Evidence from a sheep model of pregnancy. American Journal of Reproductive Immunology, 2017, 77, e12599.	1.2	6
81	Viral Heparin-Binding Complement Inhibitors – A Recurring Theme. , 2007, 598, 105-125.		6
82	Measurement of C3 Fragment Deposition on Cells. , 2000, 150, 131-137.		5
83	Molecular typing ofMycoplasma pneumoniae: where do we stand?. Future Microbiology, 2015, 10, 1793-1795.	1.0	5
84	Detrimental Effects of an Inhaled Phosphodiesterase-4 Inhibitor on Lung Inflammation in Ventilated Preterm Lambs Exposed to Chorioamnionitis Are Dose Dependent. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2019, 32, 396-404.	0.7	5
85	Screening of Chorioamnionitis Using Volatile Organic Compound Detection in Exhaled Breath: A Pre-clinical Proof of Concept Study. Frontiers in Pediatrics, 2021, 9, 617906.	0.9	5
86	Evaluation of the MYCOPLASMA IST3 urogenital mycoplasma assay in an international multicentre trial. Journal of Antimicrobial Chemotherapy, 2021, 76, 3175-3182.	1.3	5
87	Rat T cells express neither CD55 nor CD59 and are dependent on Crry for protection from homologous complement. European Journal of Immunology, 2002, 32, 502-509.	1.6	4
88	Isolation of Separate <i>Ureaplasma</i> Species From Endotracheal Secretions of Twin Patients. Pediatrics, 2016, 138, .	1.0	4
89	Prophylactic Intra-Uterine Î ² -Cyclodextrin Administration during Intra-Uterine Ureaplasma parvum Infection Partly Prevents Liver Inflammation without Interfering with the Enterohepatic Circulation of the Fetal Sheep. Nutrients, 2020, 12,	1.7	4
90	Role of Serine Proteases in the Regulation of Interleukin-877 during the Development of Bronchopulmonary Dysplasia in Preterm Ventilated Infants. PLoS ONE, 2014, 9, e114524.	1.1	4

#	Article	IF	CITATIONS
91	Identifying large-scale recombination and capsular switching events in Streptococcus agalactiae strains causing disease in adults in the UK between 2014 and 2015. Microbial Genomics, 2022, 8, .	1.0	4
92	Comparison of Complement Activity in Adult and Preterm Sheep Serum. American Journal of Reproductive Immunology, 2015, 73, 232-241.	1.2	3
93	Differential recognition of the multiple banded antigen isoforms across Ureaplasma parvum and Ureaplasma urealyticum species by monoclonal antibodies. Journal of Microbiological Methods, 2016, 127, 13-19.	0.7	3
94	Mycoplasma genitalium prevalence in Welsh sexual health patients: Low antimicrobial resistance markers and no association of symptoms to bacterial load. Microbial Pathogenesis, 2020, 139, 103872.	1.3	3
95	<i>Mycoplasma hominis</i> Variable Adherence-Associated Antigen: A Major Adhesin and Highly Variable Surface Membrane Protein. Advances in Microbiology, 2014, 04, 736-746.	0.3	3
96	Measurement of Complement Lysis of Nucleated Cells. , 2000, 150, 73-81.		2
97	Monoclonal anti-neutrophil elastase antibody characterisation: Ability to block function, detect free versus serpin-complexed enzyme and stain intracellular granules. Journal of Immunological Methods, 2008, 336, 175-182.	0.6	2
98	Calcium Gluconate in Phosphate Buffered Saline Increases Gene Delivery with Adenovirus Type 5. PLoS ONE, 2010, 5, e13103.	1.1	2
99	Defining Fluoroquinolone Resistance-Mediating Mutations from Non-Resistance Polymorphisms in Mycoplasma hominis Topoisomerases. Antibiotics, 2021, 10, 1379.	1.5	1
100	Determination of In Vitro Antimicrobial Susceptibility for Lefamulin (Pleuromutilin) for Ureaplasma Spp. and Mycoplasma hominis. Antibiotics, 2021, 10, 1370.	1.5	1
101	Ureaplasma-Driven Neonatal Neuroinflammation: Novel Insights from an Ovine Model. Cellular and Molecular Neurobiology, 2023, 43, 785-795.	1.7	1
102	Molecular details of the complement regulatory and cell attaching functions of KCP. Molecular Immunology, 2007, 44, 213.	1.0	0
103	Characterization of the complement inhibitory function of Rhesus rhadinovirus. Molecular Immunology, 2008, 45, 4172-4173.	1.0	0
104	Antibiotic resistance among clinical Ureaplasma isolates from Cuban individuals between 2013 and 2018. Journal of Medical Microbiology, 2022, 71, .	0.7	0